IRVINE, Calif., Oct. 26, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced it has just signed a new agreement that will provide an additional 320 acres of allotment development land in Humboldt County, Nevada. Along with production growing and processing operations, this agreement will integrate drug development, educational development, and commercial enhancements for job creation within their respective communities.
Chief Bill, stated, “We are very pleased to be working with Cannabis Science on such large scale projects. I am a member of the Allotment Family Members of Northern Nevada / Idaho Shoshoni. I Represent the Allotment Families of the Winnemucca Tribe MBS. The Tribal Allotment Families of Winnemucca covers several reservations with a total of over 5,000 acres covering several States. We signed the original deal in Ft. McDermitt allotment with the goal to bring education, the job creation and drug development programs and now this land package, as we strive to bring each tribe across the Country the same opportunity for their own economic community development. Because one of our group members already has an Industrial Hemp Research Permit and Department of Agriculture Certificate (License) in place (on one of our properties) in Southern Nevada our expansion plans are going very smoothly. We are in development (production) and expect to be in production with Cannabis Science in short order. I am in discussions with several other tribes across the nation and I expect Raymond’s vision and expertise will continue to be the architect helping us realize our aggressive growth plans and we are looking forward to it.”
This Agreement between CBIS and its contributing affiliates will facilitate outdoor and indoor operations when it comes to Hemp and Medical Marijuana, as native law permits in this specific location, with applicable licensing. All parties involved are motivated and excited with all the possibilities brought forward with this new Agreement. It gives CBIS and its investor partners access to over 300 acres in development land. Considering the size and diversity of this project, the partners needed to act in different segments with their own respective area of expertise to locate the ideal spots to commence key operations for this land package.
“This added capacity will not only benefit CBIS and it’s contributing affiliates, but also the Community with the educational component. The profound benefits are multiplied from this Agreement in many ways, including current research and programs targeting critical ailments including Cancer, PTSD, HIV/AIDS, Autism, and Neurological disorders, utilizing and monitoring different cannabinoid formulations and delivery modules. Working with Chief Bill, CBIS will have a much wider base to work from by further expanding into the State of Nevada, drawing another very large targeted medical consumer base. This Nevada opportunity was a complete surprise as we were more focused on targeting California expansions; however, of course, when new and fortuitous circumstances present themselves, you must be fluid, and open to respond accordingly. This is what we did. The added capacity this development deal and others like it should allow us to rapidly move from into a much larger development and production capacity to continue the advancement of our drug development programs while we provide our important formulations to patients in need, sooner and in greater geographic areas. We are expanding across the Nation,” stated Cannabis Science President & CEO, Co-Founder Raymond C. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.